InsiderClue
← All stocks

Crinetics Pharmaceuticals, Inc.

CRNX Net buying
CIK 0001658247 #989 in the set updated 19 Sep 2026
Bought (120 mo)
$62.80M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$95.80M
$8.89M on a plan · $42.83M straight out of an exercise
Sold at will
$44.09M
86 of 184 sales
Net
−$33.01M
+$18.71M against sales at will

By person

22 insiders · 216 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
PERCEPTIVE ADVISORS LLC entity
10% owner
$54.06M (5)
—
+$54.06M
5,321,032
5.02%
$212.84M
+1,630%
Struthers Richard Scott
President & CEO
$65.00K (2)
$23.19M (23) scheduled
−$23.12M
111,100
0.1047%
$4.44M
−91.6%
Vivo Capital VIII, LLC entity
10% owner
$6.58M (4)
$19.81M (34)
−$13.24M
298,625
0.2815%
$11.95M
—
5AM Ventures IV, L.P. entity
Former 10% holder
$1.96M (2)
$15.04M (6)
−$13.08M
94,489
0.0891%
$3.78M
—
Betz Stephen F.
Chief Scientific Officer
—
$8.75M (53) scheduled
−$8.75M
0
0.0000%
$0.00
−100.0%
Pizzuti Dana
Chief Med and Dev Officer
—
$7.11M (21) scheduled
−$7.11M
66,837
0.0630%
$2.67M
+1,584%
Knight Jeff E.
Chief Dev. & Operating Officer
—
$7.04M (11) scheduled
−$7.04M
105,289
0.0993%
$4.21M
+2,375%
Wilson Marc
CFO
—
$6.64M (9) scheduled
−$6.64M
111,092
0.1047%
$4.44M
+69.9%
Fust Matthew K
Director
—
$4.24M (12) scheduled
−$4.24M
0
0.0000%
$0.00
−100.0%
Hassard James
Chief Commercial Officer
—
$1.33M (2) scheduled
−$1.33M
29,259
0.0276%
$1.17M
—
Okey Stephanie
Director
—
$1.18M (4) scheduled
−$1.18M
0
0.0000%
$0.00
—
Madan Ajay
Chief Development Officer
—
$418.00K (2)
−$418.00K
176,995
0.1669%
$7.08M
+189.8%
Krasner Alan Seth
Chief Medical Officer
$34.00K (1)
$352.08K (2) scheduled
−$318.08K
43,210
0.0407%
$1.73M
+372.4%
Schilke Tobin
Chief Financial & Infra. Ofcr.
—
$266.30K (1) scheduled
−$266.30K
0
0.0000%
$0.00
−100.0%
Vivaldi Coelho Rogerio
Director
$110.30K (1)
$300.76K (3) scheduled
−$190.46K
0
0.0000%
$0.00
—
Kalofonos Isabel
Chief Commercial Officer
—
$137.50K (1) scheduled
−$137.50K
0
0.0000%
$0.00
−100.0%
WIERENGA WENDALL
Director
—
—
—
116,146
0.1095%
$4.65M
+55.9%
WIERENGA WENDELL
Director
—
—
—
0
0.0000%
$0.00
−100.0%
Deardorf Caren
Director
—
—
—
0
0.0000%
$0.00
—
Nichols Weston
Director
—
—
—
0
0.0000%
$0.00
—
Bedrosian Camille L
Director
—
—
—
0
0.0000%
$0.00
—
Versant Venture Capital V, L.P. entity
10% owner
—
—
—
0
0.0000%
$0.00
—

Individual transactions

17
Insider
Date
Role
Action
Shares
Price
Amount
Struthers Richard Scott
7 Aug 2026
President & CEO
Exercised, kept
4,995
$20.02
$100.00K
Struthers Richard Scott
7 Aug 2026
President & CEO
Exercised, kept
6,542
$15.29
$100.03K
Struthers Richard Scott
7 Aug 2026
President & CEO
Exercised, kept
4,422
$22.61
$99.98K
Struthers Richard Scott
7 Aug 2026
President & CEO
Exercised, kept
3,969
$25.19
$99.98K
Betz Stephen F.
26 Dec 2025
Chief Scientific Officer
Exercised, kept
18,000
$1.91
$34.38K
Struthers Richard Scott
18 Dec 2025
President & CEO
Exercised, kept
28,400
$15.29
$434.24K
Struthers Richard Scott
18 Dec 2025
President & CEO
Exercised, kept
16,342
$9.28
$151.65K
Struthers Richard Scott
2 Apr 2025
President & CEO
Exercised, kept
81,270
$1.91
$155.23K
Pizzuti Dana
7 Jan 2025
Chief Med and Dev Officer
Exercised, kept
2,500
$19.64
$49.10K
Betz Stephen F.
16 Dec 2024
Chief Scientific Officer
Exercised, kept
2,331
$1.91
$4.45K
Struthers Richard Scott
15 Apr 2024
President & CEO
Exercised, kept
20,000
$1.91
$38.20K
Struthers Richard Scott
9 Nov 2023
President & CEO
Exercised, kept
50,000
$1.91
$95.50K
Struthers Richard Scott
14 Aug 2023
President & CEO
Exercised, kept
10,000
$1.91
$19.10K
Struthers Richard Scott
12 Oct 2022
President & CEO
Exercised, kept
11,100
$1.91
$21.20K
Madan Ajay
28 Oct 2021
Chief Development Officer
Exercised, kept
106,383
$0.73
$77.66K
WIERENGA WENDALL
28 Apr 2020
Director
Exercised, kept
25,329
$0.73
$18.49K
Struthers Richard Scott
5 Aug 2019
President & CEO
Exercised, kept indirect
10,000
$1.91
$19.10K
Show all 216 transactions →

What was left out

Form 4 filings counted 272
Amendments (4/A) skipped 3
Filings about a different issuer 0
Unreadable filings 0
Joint filings 20
Sales on a Rule 10b5-1 plan 46
Sales straight out of an exercise 52
Sales at will 86
Transactions with no price 0
Shares from compensation/vesting 22,218,718
Sales filed before the plan box existed 86
History held since 20 Jul 2018